Westrock Coffee (WEST) Q1 2026 earnings review
The Inflection Point Reached: Capex Collapses, EBITDA Triples
Westrock Coffee has officially transitioned from a multi-year construction phase into operational harvesting. With all five lines at the Conway facility fully commercialized, Q1 revenue surged 44% YoY to $308.8M, and Adjusted EBITDA more than tripled to $26.0M. Crucially, the structural shift in capital intensity is evident: CapEx plummeted 83% YoY. However, despite the massive profitability improvement at the EBITDA level, the company remains unprofitable on a net income basis and continues to burn cash, indicating the operational turnaround hasn't fully trickled down to the bottom line yet. Management reaffirmed FY26 EBITDA guidance of $90-100M.
🐂 Bull Case
The massive investment phase is in the rearview mirror. All five production lines are live, driving sequential and YoY volume growth and enabling a major drop in capital expenditures.
Management's 'one-stop shop' strategy is working. Brands are expanding beyond single SKUs and adopting the full spectrum of Westrock's beverage partnerships, accelerating top-line momentum.
🐻 Bear Case
Despite a massive jump in Adjusted EBITDA, Westrock still posted a net loss of $8.5M and negative operating cash flow of $11.8M due to working capital and derivative swings.
Total debt remains over $500M. Combining this with high green coffee prices and significant Brazilian tariffs means liquidity and working capital remain under pressure.
⚖️ Verdict: 🟢
Bullish. The financial inflection point management promised has arrived. The crossover where EBITDA structurally exceeds CapEx is a massive milestone, even though working capital needs require monitoring.
Key Themes
Conway Scale-Up Complete
After nearly three years of construction, cost overruns, and scale-up challenges, the Conway extract and RTD facility is officially fully commercialized across all five lines. This is the primary engine behind the 44% revenue jump and the massive 143% expansion in the Beverage Solutions segment's Adjusted EBITDA.
Sustainable Sourcing & Traceability (SS&T) Outperformance
The SS&T segment continues to punch above its weight. Net sales grew 40% YoY to $69.5M, and Segment Adjusted EBITDA accelerated dramatically, leaping 242% from $1.9M to $6.5M. The segment is demonstrating excellent operational leverage.
Structural Shift in Capital Intensity
Management delivered on the promise to halt heavy spending. Q1 CapEx was just $7.1M, a precipitous drop from $41.3M a year ago. The company is pivoting from building infrastructure to optimizing operations and focusing on free cash flow generation.
Cash Burn Contradicts EBITDA Victory
Despite reporting $26.0M in Adjusted EBITDA, actual Operating Cash Flow was negative $11.8M, primarily driven by a $27.1M outflow from derivative assets and liabilities, and negative working capital movements. Consequently, Free Cash Flow remains negative ($18.9M). The 'record' earnings haven't structurally fixed the cash bleed yet.
Macro Pressures: Tariffs and Coffee Prices
Persistently high green coffee prices and massive tariffs on Brazilian beans (flagged in 2025 calls as a 50% hit) continue to weigh on the business. Management previously warned that while costs are passed through, they create significant short-term pressure on working capital and liquidity, a dynamic visibly playing out in Q1's negative operating cash flow.
Single-Serve Customer M&A Fallout
In Q3 2025, management explicitly warned that a major single-serve cup customer was involved in an M&A transaction, placing 2026 volumes at risk. The current release completely omits any update on whether this 'whale' customer's volume was retained or lost, leaving a major shadow over forward visibility.
Other KPIs
Accelerating. Gross margin expanded from 13.6% in 25Q1 to 14.8% in 26Q1, driven by the leverage gained from the newly commercialized Conway facility. Gross profit dollars jumped 57.4%, significantly outpacing the 44.4% revenue growth.
Improving. Dropped meaningfully from 3.85x at the end of FY25 and sits comfortably below the covenant limit. The ratio improvement is almost entirely driven by the rapid expansion of Trailing Twelve-Month Credit Agreement Adjusted EBITDA ($94.7M), rather than debt reduction, as secured net debt actually increased slightly.
Guidance
Accelerating. Reaffirmed from March 2026. The midpoint ($95.0M) implies a robust 36% YoY growth compared to FY25's $69.7M. Given Q1 delivered $26.0M, the company is tracking slightly ahead of the required run rate, adding credibility to the full-year target.
Key Questions
Single-Serve M&A Attrition
In Q3 2025, you flagged that a major single-serve customer's 2026 volume was highly uncertain due to an M&A event. Did you lose that volume, and if so, how much of it has been backfilled by the 'full spectrum' customer demand mentioned in the release?
Path to Positive Free Cash Flow
EBITDA tripled and CapEx collapsed, yet Operating Cash Flow remained negative in Q1 due to working capital and derivative swings. At what specific point in FY26 do you expect to generate sustainable, positive Free Cash Flow?
Debt Reduction Strategy
With the heavy Conway CapEx phase officially behind you and the leverage ratio down to 3.45x, will the company begin prioritizing absolute debt paydown with generated cash, or will capital be redirected toward new product categories like the high-protein lines mentioned last year?